BioNote vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how BioNote (377740) and Abbott Laboratories (ABT) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: BioNote trades at KRW 4,900 versus a fair value of KRW 2,782 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
BioNote
377740.KO · KRW · Health Care
-43%
upside to fair value
overvalued
PriceKRW 4,900
Fair ValueKRW 2,782
Quality54/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
BioNoteAbbott Laboratories
Valuation
—P/E (TTM)27.7×
—P/S (TTM)3.89×
—P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
5.1%Dividend yield—
KRW 228Dividend per share—
Profitability
-41%Net margin14%
20%Operating margin13%
-3%Return on equity12%
1%Return on assets6%
Growth
15%Revenue growth (YoY)8%
-37.3%Avg. growth/yr (3Y)0.5%
-28.5%Avg. growth/yr (5Y)5.1%
Balance & size
—Debt / equity0.19×
$312MMarket cap$175B
weakGrowth qualityhealthy
Abbott Laboratories leads: 2 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
BioNoteof which business quality 51 · market factors 46Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
2
50
Quality GrowthAre margins and returns improving?
45
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
91
65
Low VolatilityCalm price path (market factor)
78
83
MomentumPrice trend over the last 3–12 months (market factor)
33
40
52W MomentumDistance to the 52-week high (market factor)
33
33
Net IssuanceBuybacks instead of dilution
86
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
BioNote
DCF ModelsKRW 3,066
Earnings-BasedKRW 1,728
MultiplesKRW 3,014
Asset-BasedKRW 10,050
Growth DCFKRW 2,661
Economic ProfitKRW 1,728
12 of 13 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
BioNote
Bear KRW 1,660Fair Value KRW 2,782Bull KRW 3,491
KRW 4,900 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
BioNote · Health Care
Quality score54 · above median
Fair value upside-43% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: BioNote trades at KRW 4,900 versus a fair value of KRW 2,782 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
